ArticleCellular and molecular gastroenterology and hepatology2026
Dysbiosis-Associated Lysophosphatidic Acid Primes Immune Checkpoint Inhibitor-Induced Intestinal Barrier Dysfunction via the Lysophosphatidic Acid Receptor 2-Myosin Light Chain Kinase Axis.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsImmune checkpoint inhibitor therapy is frequently limited by severe gastrointestinal toxicity. Although the immune mechanisms driving late-stage, overt mucosal inflammation are increasingly recognized, the early microbiota-metabolic events that prime epithelial barrier dysfunction remain poorly defined.
methodsWe employed an integrated multiomics approach in a murine model of early immune checkpoint inhibitor-induced injury, with validation in a clinical cohort of patients with immune checkpoint inhibitor colitis. Mechanisms were investigated using in vitro receptor screening, genetically engineered mice with altered myosin light chain kinase 1 activity, and pharmacologic intervention with repurposed low-dose tacrolimus. Subcutaneous melanoma models were utilized to evaluate the relationship between barrier modulation and antitumor outcomes.
resultsEarly immune checkpoint inhibitor treatment induced a distinct dysbiotic state characterized by Pseudomonadota expansion, which was associated with the accumulation of bioactive lysophosphatidic acid-a metabolic signature also observed in human patients. Mechanistically, we identified lysophosphatidic acid receptor 2 as the key epithelial sensor that transduces this metabolic signal into pathological myosin light chain kinase 1 activation, driving the priming phase of barrier dysfunction. Genetic ablation of myosin light chain kinase 1 prevented this early barrier loss and was associated with improved tumor control and favorable regional immune alterations. Conversely, constitutive activation of myosin light chain kinase 1 exacerbated barrier disruption, which correlated with accelerated tumor progression and a systemic immunosuppressive shift. Furthermore, repurposing low-dose tacrolimus as a selective modulator to disrupt FKBP8-dependent myosin light chain kinase 1 recruitment effectively mitigated barrier injury without dampening antitumor responses.
conclusionsThe dysbiosis-associated lysophosphatidic acid-lysophosphatidic acid receptor 2-myosin light chain kinase axis acts as an early metabolic trigger for the priming phase of immune checkpoint inhibitor-induced barrier dysfunction. Modulating this upstream initiation step provides a temporal and mechanism-based strategy to uncouple intestinal toxicity from anti-tumor efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.